So-caArget. Influence the deliberate use of these so-called polypharmacologics RTK multiple processes or multiple related cancer such as tumor AV-951 cell proliferation and angiogenesis has recently gained wider acceptance and is likely to see the development in the near future. Another approach to chemotherapy con U fa Rational we saw increased Hte attention sp Th focus on the combination of compounds that activate the pathways commonly happy t target that the individual molecules oncogenes. Since activate many of RTK involved in NSCLC Hnlichen downstream effectors, targeting common ways pleased t that multiple receptors may be an effective alternative to chemotherapy. Various medications that mTOR Ras / MAPK, PI3K/Akt and JAK / STAT pathways are inhibited, in clinical development as a single agent or in combination.
The BIX 02189 use of these substances can be more effective as targeting individual because the mutational spectrum for RTK receiver singer much larger He is less than the number of signal paths of these molecules activated. The question of whether targeted therapies additionally offer USEFUL advantages in combination with radiotherapy or cytotoxic chemotherapy is also a large e clinical interest because XRTand / or CC remains the standard of care for unresectable or advanced NSCLC. Several Phase 2/3 clinical trials have begun Including this issue through the simultaneous use of sorafenib or more EGFR inhibitors with agents of the CC Lich platinum-based drugs, to answer the beautiful dlichen substances DNA and taxanes, or in combination with XRT.
The results of these studies have been almost uniformly Moderately disappointed Uschend and show little, if any, zus Tzlichen advantage of combination therapy on CC or CC and combined XRT alone. Since most of these studies were conducted in select groups of patients, but it remains to be seen whether the combinatorial treatment with CC or XRT and targeted therapies for patients with L results Sions improve genetically determined. It was also suggested that each m Possible benefits of the combination treatment rather serial pleased t that co-treatment or maintenance CC, since targeted drugs including normal TKIs h Can frequently arise proliferationdependent a cytostatic mechanisms to avoid being Zellzerst tion by cytotoxic therapeutic methods when used simultaneously.
Whatever the treatment paradigm has proven to be most effective, it is clear that NSCLC should be treated with an approach to personalized medicine, if chemotherapy is a big success he be in the hospital. This approach requires that each patient changes a treatment group on the specific constellation of molecular compounds Defining the disease is based, can be assigned. W While most tangible methods of segregation is currently based on the sequential lacing limited gene expression data, it is likely that more sophisticated Ans PageSever including normal sequential lacing the entire genome, epigenome profiling, profiling and proteomics, miRNA profiling can be used to provide a more complete picture of the biology of lung cancer. Although the full range of analyzes, it is unlikely clinical benefit in the near future, the gradual introduction of individual procedures in the clinical practice of targeted rationally find desi.